19
Oral progestin tablets (cont'd)
Nomegestrol acetate
b
3.75, 5 mg/d
Promegestone
b
0.125, 0.25, 0.5 mg/d
Oral progesterone capsule
Micronized progesterone 100, 200 mg/d In peanut oil; avoid if
peanut allerg y
May cause drowsiness and
should be taken at bedtime
Intrauterine system progestin
c
LNorg 20 µg released/d
6 µg/d
IUD for 5-y use
IUD for 3-y use
Vaginal gel progesterone
c
4%, 8% 45- or 90-mg applicator
Combination hormone therapies
Oral
CEE + MPA 0.3–0.625 mg/1.5–5 mg/d Cyclic or continuous
E2 + Neta 0.5–1 mg/0.1 – 0.5 mg/d Continuous
E2 + drospirenone 0.5–1 mg/0.25 –1 mg/d Continuous
E2 + norgestimate 1 mg, 1/0.09 mg/d Cycle 3 d E alone,
3 d E + progesterone
E2 + dydrogesterone
b
1–2 mg/5–10 mg/d Cyclic and continuous
E2 + cyproterone acetate
b
2 mg/1 mg/d Continuous
E2 + MPA
b
1–2 mg/2 –10 mg/d Continuous
CEE + BZA
d
0.45 mg/20 mg/d Continuous
Transdermal
E2 + Neta 50 µg/0.14 – 0.25 mg/patch Twice weekly
E2 + LNorg 45 µg/0.015 mg/patch Once weekly
a
Not all preparations and doses are available in all countries.
b
Only available outside the United States.
c
Not approved in the United States for endometrial protection when administered with
postmenopausal estrogen.
d
Approved indications in the United States include treatment of moderate to severe VMS associated
with menopause and prevention of postmenopausal osteoporosis. In the European Union, the
indications state: treatment of estrogen deficiency symptoms in postmenopausal women with a
uterus (with at least 12 mo since the last menses) for whom treatment with progestin-containing
therapy is not appropriate. e experience treating women older than 65 years is limited.
Table 10. Commonly Prescribed Hormone Therapies (cont'd)
Preparation Doses Comments
